Trial Profile
Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study in Subjects With Relapsing Forms of Multiple Sclerosis to Evaluate the Effects of Different CDP323 Doses on Biomarker Patterns as Well as on Safety and Tolerability.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs CDP 323 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors UCB
- 11 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 20 Aug 2008 New trial record.